Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Oct-Dec;7(4):270-272.
doi: 10.4103/sajc.sajc_269_17.

Clinicopathological features, treatment and survival outcomes of synovial sarcoma

Siva Prasad Kuruva  1 , Stalin Bala  1 , Meher Lakshmi Konatam  1 , Ashok Kumar Karnam  1 , Lakshmi Srinivas Maddali  1 , Sadashuivudu Gundeti  1
Affiliations

Clinicopathological features, treatment and survival outcomes of synovial sarcoma

Siva Prasad Kuruva et al. South Asian J Cancer. 2018 Oct-Dec.

Abstract

Introduction: Synovial sarcoma (SS) is a malignant mesenchymal tumor. It is most common among children and adults. The data on SS from India are scarce. In this study, we analyzed the clinicopathological treatment parameters and survival outcomes of SS patients.

Materials and methods: A total of 57 histologically proven SS diagnosed from 2010 to 2016 were retrospectively analyzed.

Results: The median age was 23 years with a male-to-female ratio of 1.28:1. Localized disease was seen in 44 patients (77%) and 13 patients (23%) had metastasis. The primary sites of involvement such as lower limb, upper limb, thorax, and abdomen were seen in 60%, 28%, 7%, and 5% patients, respectively. Surgery was done in 39 patients and 18 patients had unresectable disease. Adjuvant chemotherapy with doxorubicin-based regimen was given in 30 patients and adjuvant radiotherapy in 21 patients. Palliative chemotherapy with anthracycline-based or gemcitabine-based regimen was used in 17 and 2 patients, respectively. The median event-free survival (EFS) was 30 months with 3 years and EFS rate was 36%; median progression-free survival (PFS) was 11.5 months and 1 year; and PFS rate was 38%. On univariate analysis, resection and performance status were significantly associated with survival. There is no impact of grade and size of the tumor on survival. In metastatic patients, the lung is the most common site.

Conclusion: SS is the most common soft-tissue sarcoma among adults. Resectability and performance status were impacting the survival.

Keywords: Clinicopathological; survival; synovial sarcoma; treatment.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Figures

Figure 1
Figure 1
Kaplan–Meier estimates showing progression-free survival
Figure 2
Figure 2
Kaplan–Meier estimates showing effect of performance status on event-free survival
Figure 3
Figure 3
Kaplan–Meier estimates showing effect of resection on event-free survival
Figure 4
Figure 4
Kaplan–Meier estimates showing effect of grade on event-free survival
Figure 5
Figure 5
Kaplan–Meier estimates showing effect of tumor size on event-free survival
See this image and copyright information in PMC

References

    1. Fisher C, de Bruijn DR, Geurts van Kessel A. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Soft Tissue and Bone. Tumours of Uncertain Differentiation Synovial Sarcoma. Ch. 9. International Agency for Research on Cancer Press. 2006
    1. Ramaswamy A, Rekhi B, Bakhshi S, Hingmire S, Agarwal M. Indian data on bone and soft tissue sarcomas: A summary of published study results. South Asian J Cancer. 2016;5:138–45. - PMC - PubMed
    1. Iqbal N, Shukla NK, Deo SV, Agarwala S, Sharma DN, Sharma MC, et al. Prognostic factors affecting survival in metastatic soft tissue sarcoma: An analysis of 110 patients. Clin Transl Oncol. 2016;18:310–6. - PubMed
    1. Haldar M, Randall RL, Capecchi MR. Synovial sarcoma: From genetics to genetic-based animal modeling. Clin Orthop Relat Res. 2008;466:2156–67. - PMC - PubMed
    1. Ladanyi M. Fusions of the SYT and SSX genes in synovial sarcoma. Oncogene. 2001;20:5755–62. - PubMed